Trials / Completed
CompletedNCT03850873
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
A Phase I Clinical， Tolerance and Pharmacokinetic Evaluation of 1 Schedules of Oral TQB3616，A Cyclin-Dependent Kinase Inhibitor ，In Patients With Advanced Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TQB3616 may work in cancer by stopping cancer cells from multiplying.TQB3616 is in a new class of drugs called CDK inhibitors.This research study is the first time that TQB3616 will be given to people.TQB3616 is taken by mouth daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3616 | TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily |
Timeline
- Start date
- 2019-05-20
- Primary completion
- 2021-09-23
- Completion
- 2021-09-23
- First posted
- 2019-02-22
- Last updated
- 2026-04-09
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03850873. Inclusion in this directory is not an endorsement.